Terms: = Kidney tumors AND CUX1, ENSG00000160967, P39880, p75, p200, p110, p100, Nbla10317, CUX, COY1, CDP, CASP, 1523 AND Treatment
18 results:
1. Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer treatment.
Abbas ZS; Sulaiman GM; Jabir MS; Mohammed SAA; Khan RA; Mohammed HA; Al-Subaiyel A
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889394
[TBL] [Abstract] [Full Text] [Related]
2. Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1-a systematic review.
Junker T; Duus L; Rasmussen BSB; Azawi N; Lund L; Graumann O; Nørgaard B
Syst Rev; 2022 Jan; 11(1):4. PubMed ID: 34983648
[TBL] [Abstract] [Full Text] [Related]
3. Small renal masses in Latin-American population: characteristics and prognostic factors for survival, recurrence and metastasis - a multi-institutional study from LARCG database.
Mourão TC; Abreu D; Carvalhal GF; Gueglio G; da Costa WH; Calsavara VF; Meza-Montoya L; Bengió RG; Scorticati C; Castillejos-Molina R; Rodríguez-Covarrubias F; Autran-Gómez AM; Campos-Salcedo JG; Nolazco A; Ameri C; Zampolli H; Langenhin R; Muguruza D; Machado MT; Mingote P; Clavijo J; Nogueira L; Clark O; Rovegno AR; Secin FP; Decia R; Guimarães GC; Glina S; Rodríguez-Faba O; Palou J; Zequi SC
BMC Urol; 2020 Jul; 20(1):85. PubMed ID: 32615971
[TBL] [Abstract] [Full Text] [Related]
4. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
[TBL] [Abstract] [Full Text] [Related]
5. Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study.
Hasegawa T; Yamanaka T; Gobara H; Miyazaki M; Takaki H; Sato Y; Inaba Y; Yamakado K
Jpn J Radiol; 2018 Sep; 36(9):551-558. PubMed ID: 29968201
[TBL] [Abstract] [Full Text] [Related]
6. Patient preference for stereotactic radiosurgery plus or minus whole brain radiotherapy for the treatment of brain metastases.
Zeng KL; Raman S; Sahgal A; Soliman H; Tsao M; Wendzicki C; Chow E; Lo SS
Ann Palliat Med; 2017 Dec; 6(Suppl 2):S155-S160. PubMed ID: 28866900
[TBL] [Abstract] [Full Text] [Related]
7. Epidemiology of epistaxes admitted to a tertiary hospital.
Monjas-Cánovas I; Hernández-García I; Mauri-Barberá J; Sanz-Romero B; Gras-Albert JR
Acta Otorrinolaringol Esp; 2010; 61(1):41-7. PubMed ID: 20004879
[TBL] [Abstract] [Full Text] [Related]
8. Three-dimensional assessment of MR imaging-guided percutaneous cryotherapy using multi-performer repeated segmentations: the value of supervised learning.
Zou KH; Tuncali K; Warfield SK; Zentai CP; Worku D; Morrison PR; Silverman SG
Acad Radiol; 2005 Apr; 12(4):444-50. PubMed ID: 15831417
[TBL] [Abstract] [Full Text] [Related]
9. Sonographic detection of uterine and ovarian abnormalities in female survivors of Wilms' tumor treated with radiotherapy.
Nussbaum Blask AR; Nicholson HS; Markle BM; Wechsler-Jentzch K; O'Donnell R; Byrne J
AJR Am J Roentgenol; 1999 Mar; 172(3):759-63. PubMed ID: 10063876
[TBL] [Abstract] [Full Text] [Related]
10. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells.
Suzuki N; Urano J; Tamanoi F
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15356-61. PubMed ID: 9860973
[TBL] [Abstract] [Full Text] [Related]
11. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract] [Full Text] [Related]
12. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
[TBL] [Abstract] [Full Text] [Related]
13. Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer.
Schuler M; Peschel C; Schneller F; Fichtner J; Färber L; Huber C; Aulitzky WE
J Interferon Cytokine Res; 1996 Nov; 16(11):903-10. PubMed ID: 8938565
[TBL] [Abstract] [Full Text] [Related]
14. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
Canpolat C; Pearson P; Robertson R; Jaffe N
Med Pediatr Oncol; 1996 Jan; 26(1):36-47. PubMed ID: 7494510
[TBL] [Abstract] [Full Text] [Related]
15. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract] [Full Text] [Related]
16. Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.
Landmann R; Keilholz U; Scheibenbogen C; Brockhaus M; Gallati H; Denz H; Bargetzi M; Ludwig C
Cancer Immunol Immunother; 1994 Feb; 38(2):113-8. PubMed ID: 8306366
[TBL] [Abstract] [Full Text] [Related]
17. Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera.
Tilg H; Shapiro L; Atkins MB; Dinarello CA; Mier JW
J Immunol; 1993 Sep; 151(6):3299-307. PubMed ID: 8397255
[TBL] [Abstract] [Full Text] [Related]
18. Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.
Miles DW; Aderka D; Engelmann H; Wallach D; Balkwill FR
Br J Cancer; 1992 Dec; 66(6):1195-9. PubMed ID: 1333789
[TBL] [Abstract] [Full Text] [Related]
